Opinion|Videos|August 5, 2024
Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC
The panel of experts in lung cancer examines genetic alterations affecting treatment response and biomarker testing rates in metastatic non-small cell lung cancer (mNSCLC).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance?
- In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Clears First Alzheimer Blood Test for Adults as Young as 40
2
RSV Vaccine Shows 100% Effectiveness in COPD: Jorgen Vestbo, MD
3
5 Things to Know About the 2026 ESC Heart Failure Guidelines
4
FDA Shortens Tarlatamab Monitoring, Widens Access to SCLC Care
5